Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERMAD: Early Switch to Aflibercept in mCRC
NCT02331927Phase 2Unknown
- Sponsor
- Ulm University
- Start
- Mar 2015
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Ulm University. Primary endpoints: Progression free survival of first line treatment and Progression free survival rate at 6 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02331927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331927.